A Review of the Rational and Current Evidence on Colchicine for COVID-19

被引:3
|
作者
Ghaith, Hazem S. [1 ]
Gabra, Mohamed Diaa [2 ]
Nafady, Mohamed H. [3 ]
Elshawah, Hamza Emad [4 ]
Negida, Ahmed [5 ,6 ]
Mushtaq, Gohar [7 ]
Kamal, Mohammad Amjad [8 ,9 ,10 ,11 ]
机构
[1] Al Azhar Univ, Fac Med, Cairo, Egypt
[2] South Valley Univ, Fac Med, Qena, Egypt
[3] Misr Univ Sci & Technol, Fac Appl Med Sci, 6th October City, Egypt
[4] Al Azhar Univ, Fac Med, New Damietta, Egypt
[5] Zagazig Univ, Fac Med, Zagazig, Egypt
[6] Univ Portsmouth, Sch Pharm & Biomed Sci, Portsmouth, England
[7] Idlib Univ, Fac Med, Ctr Sci Res, Idlib, Syria
[8] Sichuan Univ, West China Hosp, Inst Syst Genet, Frontiers Sci Ctr Dis Related Mol Network, Chengdu, Peoples R China
[9] King Abdulaziz Univ, King Fahd Med Res Ctr, Jeddah 21589, Saudi Arabia
[10] Daffodil Int Univ, Fac Allied Hlth Sci, Dept Pharm, Dhaka 1207, Bangladesh
[11] Enzymoics, Novel Global Community Educ Fdn, 7 Peterlee Pl, Hebersham, NSW 2770, Australia
关键词
Anti-inflammatory agents; immunosuppressive agents; immune modulators; colchicine; COVID-19; SARS-CoV-2; CORONAVIRUS; PROTEIN; ACE2;
D O I
10.2174/1381612827666211210142352
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The current coronavirus disease (COVID-19) pandemic has affected millions of individuals worldwide. Despite extensive research efforts, few therapeutic options currently offer direct clinical benefits for COVID-19 patients. Despite the advances in our understanding of COVID-19, the mortality rates remain significantly high owing to the high viral transmission rates in several countries and the rise of various mutations in the SARS-CoV-2. One currently available and widely used drug that combines both anti-inflammatory and immunomodulatory actions is colchicine, which has been proposed as a possible treatment option for COVID-19. Colchicine still did not get much attention from the medical and scientific communities despite its anti-inflammatory and immunomodulatory mechanisms of action and positive preliminary data from early trials. This literature review article provides the scientific rationale for repurposing colchicine as a potential therapy for COVID-19. Further, we summarize colchicine's mechanisms of action and possible roles in COVID-19 patients. Finally, we supplement this review with a summary of the doses, side effects, and early efficacy data from clinical trials to date. Despite the promising early findings from multiple observational and clinical trials about the potential of colchicine in COVID-19, the data from the RECOVERY trial, the largest COVID-19 randomized controlled trial (RCT) in the world, showed no evidence of clinical benefits in mortality, hospital stays, or disease progression (n = 11340 patients). However, multiple other smaller clinical trials showed significant clinical benefits. We conclude that while current evidence does not support the use of colchicine for treating COVID-19, the present body of evidence is heterogeneous and inconclusive. The drug cannot be used in clinical practice or abandoned from clinical research without additional large RCTs providing more robust evidence. At present, the drug should not be used except for investigational purposes.
引用
收藏
页码:3194 / 3201
页数:8
相关论文
共 50 条
  • [1] COVID-19 and Prostatitis: A Review of Current Evidence
    Daneshwar, Datesh
    Lee, Yemin
    Nordin, Abid
    DISEASES, 2024, 12 (07)
  • [2] Colchicine in the management of Covid-19: With or lieu of evidence
    Al-Kuraishy, Hayder Mutter
    Hussien, Nawar Raad
    Al-Niemi, Marwa Salih
    Al-Gareeb, Ali Ismail
    JOURNAL OF THE PAKISTAN MEDICAL ASSOCIATION, 2021, 71 (12) : S127 - S132
  • [3] Severity of COVID-19 in pregnancy: A review of current evidence
    Kucirka, Lauren M.
    Norton, Alexandra
    Sheffield, Jeanne S.
    AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY, 2020, 84 (05)
  • [4] COVID-19 in the Pediatric Population—Review and Current Evidence
    Shira Rabinowicz
    Eyal Leshem
    Itai M. Pessach
    Current Infectious Disease Reports, 2020, 22
  • [5] Gastrointestinal Disease and COVID-19: A Review of Current Evidence
    Chen, Fei
    Dai, Zhiqing
    Huang, Chaofan
    Chen, Huiran
    Wang, Xinyi
    Li, Xinya
    DIGESTIVE DISEASES, 2022, 40 (04) : 506 - 514
  • [6] THE COVID-19 PANDEMIC: A SYSTEMATIC REVIEW OF THE CURRENT EVIDENCE
    Ghomi, R.
    Asgari, N.
    Hajiheydari, A.
    Esteki, R.
    Biyabanaki, F.
    Nasirinasab, F.
    INFEKTSIYA I IMMUNITET, 2020, 10 (04): : 655 - 663
  • [7] COVID-19 pandemic: A review based on current evidence
    Mahalmani, Vidya M.
    Mahendru, Dhruv
    Semwal, Ankita
    Kaur, Sukhmeet
    Kaur, Harpinder
    Sarma, Phulen
    Prakash, Ajay
    Medhi, Bikash
    INDIAN JOURNAL OF PHARMACOLOGY, 2020, 52 (02) : 117 - 129
  • [8] Efficacy of tocilizumab in COVID-19: A review of the current evidence
    Alam, Walid
    Bizri, Abdul Rahman
    SCIENCE PROGRESS, 2021, 104 (03)
  • [9] Colchicine and COVID-19
    Corral, Pablo
    Corral, Gonzalo
    Diaz, Rafael
    JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 60 (08): : 978 - 978
  • [10] Late Complications of COVID-19; a Systematic Review of Current Evidence
    SeyedAlinaghi, SeyedAhmad
    Afsahi, Amir Masoud
    MohsseniPour, Mehrzad
    Behnezhad, Farzane
    Salehi, Mohammad Amin
    Barzegary, Alireza
    Mirzapour, Pegah
    Mehraeen, Esmaeil
    Dadras, Omid
    ARCHIVES OF ACADEMIC EMERGENCY MEDICINE, 2021, 9 (01)